CRUK's Commercial Partnerships team publish their commitments to the academic research community

Published date:
July 1 2021

Cancer Research UK's Commercial Partnerships team share four commitments on how they’ll support cancer researchers with their translational journey

01 JULY 2021 – The Commercial Partnerships (CP) team at Cancer Research UK (CRUK) develop and commercialise promising ideas into successful cancer therapeutics, vaccines, diagnostics and enabling technologies. The team supports cancer researchers to translate their research into products for patient benefit. Today, they share four commitments on how they’ll support cancer researchers with their translational journey. 

CP's relationship with researchers is at the heart of their ambition to translate great science. To make it easy for researchers to work with the team, they aim to be transparent, honest and communicative during the translational journey.

> Read the four commitments

Notes to editors

About Cancer Research UK’s Commercial Partnerships Team

Cancer Research UK is the world’s leading cancer charity dedicated to saving lives through research. Cancer Research UK’s specialist Commercial Partnerships Team works closely with leading international cancer scientists and their institutes to protect intellectual property arising from their research. The Commercial Partnerships team enables delivery of patient impact through employing commercial models ranging from traditional licensing and collaborations through to spin-out company formation and innovative industry alliances in both drug discovery and non-therapeutic areas. Cancer Research UK’s commercial activity operates through Cancer Research Technology Ltd., a wholly owned subsidiary of Cancer Research UK. It is the legal entity which pursues drug discovery research in themed alliance partnerships and delivers varied commercial partnering arrangements.